Fresh out of the blue­bird bio on­col­o­gy split, Joanne Smith-Far­rell flies the coop to Be Bio and its B cell plat­form

5 years ago
People
Cell/Gene Tx

FTC pledges to ag­gres­sive­ly crack down on phar­ma merg­ers

5 years ago
Pharma
FDA+

Roche builds long-term case for Evrys­di with 2-year SMA da­ta; Ex­e­Vir nets $50M Se­ries A for lla­ma-de­rived Covid ...

5 years ago
News Briefing

Covid-19 roundup: As As­traZeneca deals with vac­cine woes, US turns at­ten­tion to its an­ti­body treat­ment; Mod­er­na dos­es ...

5 years ago
Coronavirus

With all the buzz in gene ther­a­py, Sanofi of­floads two small mol­e­cule sick­le cell pro­grams from $11.6B buy­out to ...

5 years ago
Deals

Can a CRISPR start­up suc­ceed where Pfiz­er, Glax­o­SmithK­line, Bio­gen and Genen­tech failed and cure chron­ic pain?

5 years ago
Startups
Discovery

Mer­ck wins pri­or­i­ty re­view for rare car­ci­no­ma drug belzu­ti­fan, the cen­ter­piece of $1B+ Pelo­ton buy­out

5 years ago
FDA+

Eli Lil­ly's IL-23 in­hibitor mirik­izum­ab shows late-stage promise in ul­cer­a­tive col­i­tis — but Ab­b­Vie's Skyrizi looms

5 years ago
R&D
Pharma

Take­da, Sarep­ta dou­ble down on a biotech part­ner's plat­form to en­gi­neer bet­ter AAV cap­sids by map­ping out their ...

5 years ago
Financing
Cell/Gene Tx

FDA re­quires Re­gen­eron, Lil­ly to mon­i­tor vari­ants as a con­di­tion of mAb EUAs

5 years ago
FDA+

Tai­wan's Ace­po­dia clos­es Se­ries B with the promise of con­ju­gat­ing an­ti­bod­ies and off-the-shelf NK cells

5 years ago
Financing
Cell/Gene Tx

Ab­b­Vie looks to shed Al­ler­gan's lega­cy wom­en's health unit as it hun­kers down for Hu­mi­ra biosim dooms­day — re­port

5 years ago
Deals

No quick re­demp­tion for Glax­o­SmithK­line’s $4B al­liance with Mer­ck KGaA as bis­pe­cif­ic can­cer drug flunks a sec­ond ...

5 years ago
R&D

Sol­id Bio’s long, trou­bled slog through the clin­ic yields 'en­cour­ag­ing' ear­ly da­ta and no new safe­ty con­cerns. It's ...

5 years ago
R&D
Cell/Gene Tx

BIO chair slams Trump’s HHS, calls to stop Russ­ian dis­in­for­ma­tion cam­paign on vac­cines

5 years ago
People
Pharma

What’s in a (drug) name? FDA to study how they af­fect ef­fi­ca­cy per­cep­tions

5 years ago
FDA+

Daphne Koller lines up $400M for a glob­al shop­ping spree to vault for­ward on AI drug dis­cov­ery

5 years ago
Financing
AI

Melin­ta Ther­a­peu­tics nabs FDA nod for more con­ve­nient re­work of an­tibi­ot­ic Or­bac­tiv, a for­mer Eli Lil­ly can­di­date

5 years ago
FDA+

Galec­to shelves high dose of IPF drug af­ter SAE im­bal­ance; Long­time Aveo part­ner hands back HER3 an­ti­body

5 years ago
News Briefing

Af­ter good news in sick­le cell, blue­bird bio fol­lows up with pos­i­tive long-term da­ta in Loren­zo’s Oil dis­ease

5 years ago
Cell/Gene Tx

Vivek Ra­maswamy's LNP de­liv­ery tech play Genevant scores $600M li­cens­ing deal from Take­da for nu­cle­ic acid ther­a­pies

5 years ago
People
Deals

Covid-19 roundup: Ger­many sus­pends As­traZeneca vac­cine as British drug­mak­er de­fends shot amid blood clot scare

5 years ago
Coronavirus

Gilead, Mer­ck put aside ri­val­ry to chal­lenge Glax­o­SmithK­line for long-act­ing HIV meds

5 years ago
Deals

Next-gen gene edit­ing up­start is grab­bing the brass ring with a $150M crossover play to back its bid on a cure for ...

5 years ago
Financing
Cell/Gene Tx
First page Previous page 731732733734735736737 Next page Last page
A service from the Financial Times